April 9, 2024.
Atmo Biosciences is delighted to report that it has successfully reached its primary endpoints in a pivotal clinical study to assess whole and regional gut transit time in subjects with suspected gastrointestinal motility disorders.
December 14, 2023.
Atmo Biosciences has reached its patient recruitment target ahead of schedule for its dysmotility pivotal clinical study.
More than 200 patients were recruited in a multi-site clinical trial to support a submission for initial U.S. regulatory clearance around the use of Atmo’s gas-sensing capsule to assess gastrointestinal motility disorders.
